Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer

British Journal of Cancer

Volumn 101, Issue 8, 2009, Pages 1248-1252

  Mellado, B ^a   Font, A ^b   Alcaraz, A ^a   Aparicio, L A ^c   Veiga, F J G ^c   Areal, J ^b   Gallardo, E ^d   Hannaoui, N ^d   Lorenzo, J R M ^e   Sousa, A ^f   Fernandez, P L ^a   Gascon, P ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL DE SABADELL   (Spain)

^e Medical Oncology Service   (Spain)

^f Hospital de Monforte de Lemos   (Spain)

Author keywords

Docetaxel; High risk; Neoadjuvant therapy; Prostate cancer

Indexed keywords

ANDROGEN; ANTIEMETIC AGENT; DEXAMETHASONE; DOCETAXEL; FLUTAMIDE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER RELAPSE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FLUID RETENTION; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PLAQUETOPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE; PROSTATE CANCER; PROSTATECTOMY; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 70349952400     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605320     Document Type: Article

References (30)

1. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26: 242-245
2. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17: 3461-3467
3. Burkhard FC, Studer UE (2008) The role of lymphadenectomy in high risk prostate cancer. World J Urol 26: 231-236
4. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME (2008) Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 180: 565-570
5. DAmico A (2007) Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective - identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy. BJU Int 99: S13-S16
6. DAmico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299: 289-295
7. Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA (2004) Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63: 1138-1142 (Pubitemid 38746819)
8. Eastham JA, Kelly WK, Grossfeld GD, Small EJ, Cancer and Leukemia Group B (2003) Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone vs estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 62(Suppl 1): 55-62
9. Eigl BC, Eggener SE, Baybick J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME (2005) Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemo-hormonal therapy for prostate cancer. Clin Cancer Res 11: 4905-4909
10. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK (2005) Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11: 5233-5240
11. Friedman J, Dunn RL, Wood D, Vaishampayan U, Wu A, Bradley D, Montie J, Sarkar FH, Shah RB, Hussain M (2008) Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 179: 911-915
12. Garzotto M, Myrthue A, Higano CS, Beer TM (2006) Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 24: 254-259
13. Gleave ME, Goldenberg SL, Jones EC, Jones EC, Bruchovsky N, Sullivan LD (1996) Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155: 213-219
14. Hanfelt JJ, Slack RS, Gehan EA (1999) A modification of Simons optimal design for phase II trials when the criterion is median sample size. Control Clin Trials 20: 555-566
15. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU, Radiation Therapy Oncology Group (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduc-tion and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21: 3972-39788
16. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F, European Association of Urology (2008) EAU guidelines on prostate cancer. Eur Urol 53: 68-80
17. Heidenreich A, Ohlmann CH, Polyakov S (2007) Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52: 29-37
18. Joniau S, Van Poppel H (2008) Localized prostate cancer: can we better define who is at risk of unfavourable outcome? BJU Int 101: S5-S10
19. Kaplan E, Meier P (1975) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
20. Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA (2007) Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer 110: 1248-1254 (Pubitemid 47435595)
21. Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, Chin J, Chatterjee S, Canadian Uro-Oncology Group (2005) Long-term follow-up of a randomized trial of 0 vs 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 170: 791-794
22. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD (2006) Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 18: CD006019
23. Pendleton J, Louis MS, Pisters LL, Anai S, Rosser CJ (2007) Neoadjuvant therapy before radical prostatectomy: where have we been? Where are we going? Urol Oncol 25: 11-18
24. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520
25. Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P (2007) Long-term follow-up of a neoadjuvant chemo-hormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 100: 274-280
26. Prezioso D, Lotti T, Polito M, Montironi R (2004) Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int 72: 189-195
27. Roach III M, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26: 585-591
28. Sanda MG, Dunn RL, Michalski J, Sanda MG, Dunn RL, Michalski J (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358: 1250-1261
29. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512
30. Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, Hussain A (2006) Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 12: 169-174